ENZN
Enzon Pharmaceuticals Inc
Enzon Pharmaceuticals Inc historical holders
total: 2
Icahn Capital Management Enzon Pharmaceuticals Inc transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2015 Q3
- Held for:
- 3 quarters
- Latest activity:
- 2016 Q2
Carl Icahn has been an institutional investor in Enzon Pharmaceuticals Inc (ENZN) since 2015 Q3. According to 2026 Q1 report, Carl Icahn doesn't hold any shares. The fund/company first acquired ENZN in 2015 Q3, initially purchasing about 5.90M shares. Since the initial investment, Icahn Capital Management has made 1 more transaction in this position.
When did Carl Icahn exit their ENZN position?
Carl Icahn no longer holds Enzon Pharmaceuticals Inc (ENZN). They sold off their entire position in 2016 Q2, closing out an investment that began in 2015 Q3.
When did Carl Icahn first invest in ENZN?
Carl Icahn first invested in Enzon Pharmaceuticals Inc (ENZN) in 2015 Q3 at the reported quarter-end price of $0.97 per share, acquiring 5,904,863 shares in their initial purchase.
What is Carl Icahn's average cost basis for ENZN?
Based on historical transaction data, Carl Icahn's estimated cost basis for Enzon Pharmaceuticals Inc (ENZN) is approximately $0.97 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $0.97
- Weighted AVG sell price:
- $0.47
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.